Sanofi forecasts moderate profit growth on Dupixent demand
Sees "low single digit" percentage core EPS growth, FX adjusted
Established MS pill faces competition from cheaper products
Shares down 3%, lowest since mid-November
CEO says Dupixent "mega-blockbuster" protected beyond 2031
Adds investor comment
By Ludwig Burger
Feb 3 (Reuters) -Sanofi SASY.PA forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent would be partly offset by competition for its multiple sclerosis pill Aubagio and product launch costs.
The Paris-based drugmaker said on Friday it expected 2023 adjusted earnings per share to grow by a "low single digit" percentage, not taking into account an expected negative currency impact of between 3.5% and 4.5%.
Aubagio, with 2 billion euros ($2.2 billion) in sales last year, will face competition from cheaper products over the next few months after losing patent protection, Sanofi said.
Sanofi shares were down 3% at 1107 GMT, having earlier fallen as much as 5.2% to their lowest since mid-November with JP Morgan analysts saying investors had expected a better 2023 outlook and a more benign view on foreign exchange headwinds.
The company reaffirmed its target to achieve sales of Dupixent, jointly developed with Regeneron REGN.O, of 10 billion euros this year, up more than 20% from 8.29 billion euros in 2022.
"The results today were mixed and there's still the impression that Sanofi has a relatively weak development pipeline," said Markus Manns, portfolio manager at Germany-based Union Investment, which holds Sanofi stock.
Sanofi shares have yet to recover from a plunge in August following disappointing trial results of a once-promising breast cancer drug candidate put the strength of its development pipeline in doubt. Legal claims that heartburn drug Zantac caused cancer have also weighed on the stock.
Analysts have said that this year's expected market debut of two new products, to balance out reliance on Dupixent, would be important tests of the company's marketing prowess and a chance to regain investor confidence.
These products are haemophilia A treatment Altuviiio, requiring fewer injections than standard therapy, and Beyfortus from a partnership with AstraZeneca AZN.L, which is a preventive once-a-year shot against the common RSV airways infection in infants.
But for this year, marketing and sales expenses to boost those launches would drag earnings lower, finance chief Jean-Baptiste de Chatillon said in a media briefing.
'HOME-GROWN INNOVATION'
Chief Executive Paul Hudson pushed back when asked in a press conference whether Sanofi was too dependant on Dupixent.
"When you don’t have a mega-blockbuster people say: don’t you need a mega-blockbuster to be a success?" he said, adding the intellectual property on the product with multiple uses was protected beyond 2031.
"We understand the requirement to be ready for the 2030s and beyond and we’d like to see more of our own home-grown innovation accelerate," said Hudson. But he added that three to five drug candidates with peak annual sales potential above 1 billion euros were in the pipeline over the next six years.
Sanofi reported a 20.7% rise in fourth-quarter business operating income, or adjusted earnings before interest and tax, to 2.72 billion euros ($2.96 billion), edging past an average analyst estimate of 2.69 billion euros posted on the company's website.
Revenue from Dupixent surged 42% to 2.4 billion euros during the quarter ended Dec. 31, slightly above a consensus of 2.37 billion euros.
The French drugmaker has forecast that Dupixent would generate up to 13 billion euros in sales in its best year as it seeks to widen its use across a number of inflammatory conditions.
Investors are expecting even more on average, partly on hopes that the injection will also succeed in a trial on smoker's lung, or COPD, a common disease that the company has so far excluded from its sales target.
"The Altuviiio launch is expected to be relatively strong but the market overall will for now wait for as-yet uncertain COPD trial data on Dupixent," said mutual fund manager Manns.
Analysts expect the study result to be published during the first half.
($1 = 0.9163 euros)
Reporting by Ludwig Burger; Editing by Rashmi Aich, Matt Scuffham, Jane Merriman and Emelia Sithole-Matarise
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
